Pharma

Your Article Summary

See Latest Articles

Interim Study Results Presented at ADA 2009: Exenatide Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs
Amylin Pharmaceuticals, 06/08/09

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced interim results from a retrospective study including nearly 260,000 patients that showed the risk of acute pancreatitis among patients initiating therapy with BYETTA injection was not increased compared to patients initiating other antidiabetic therapies. These findings were presented at the 69th Annual Scientific Sessions of the American Diabetes Association in New Orleans.

Today in Conferences/Meetings...keeping you current

Receive free subspecialty "5-minute updates" via email

Quality of trials reported as conference abstracts in China: How well are they reported
International Journal of Technology Assessment in Health Care, 11/05/09

User Groups Prove Helpful
HealthDataManagement, 11/03/09

Salix Pharmaceuticals Reviews American Association For The Study Of Liver Diseases Annual Meeting
Salix Pharmaceuticals, 11/03/09

See All of Conferences/Meetings